Oxolife initiates a collaboration with the University of Cordoba and Rutgers, The State University of New Jersey, to develop a treatment to improve women’s fertility
The biotechnology company Oxolife S.L. (Spain), the Energy Balance, Puberty and Reproductive Health research group of the University of Cordoba (UCO, Spain) and the Human Growth and Reproductive Development research group at Rutgers, The State University of New Jersey, have initiated a triple international collaboration in order to further investigate the direct mechanisms of the […]
ANOTHER BIG MILESTONE FOR OXOLIFE
We are delighted to announce that OXOART2, the OXO-001 phase II clinical trial, has already started! As mentioned by the newspapers Expansion and LaVanguardia, this trial aims to demonstrate the efficacy of OXO-001 in promoting embryo implantation in assisted reproduction treatments. The study will be conducted with 351 women in 24 sites of Spain, the […]
Good feelings in the investigators meetings
On the 9th of September, we had the pleasure to meet the Czech and Polish investigators in the OXOART2 Investigators Meeting, held in Prague. It was a complete success! We are very excited to announce that the screening of candidates for the phase II clinical trial with OXO-001 has already started. Therefore, we expect to […]
OXOART2 is here: First Investigators Meeting
Last Thursday 2nd of September, we had the pleasure to celebrate the first investigator meeting of the phase II clinical trial OXOART2 in Barcelona. It was an enriching meeting where we presented the main topics of the clinical trial and got to know a bit better all the sites from Spain that will make OXOART2 […]
UNPRECEDENTED APPROACH: Oxolife shows up in El Punt Avui
OXOLIFE is developing the first drug that will treat female infertility by improving the endometrium to enhance the embryo implantation in the uterus.In the largest study that has ever been performed in Spain, 350 women from three different countries who cannot have children will be recruited.The team has managed to raise five million euros of funding. […]
OXOLIFE presents the latest results in the ASRM21
Oxolife will present its newest evidences on OXO-001 in fertility and embryo implantation in the American Society for Reproductive Medicine (ASRM) Congress, held in Baltimore (US) from the 17th to the 20th October 2021. After the recent communications at ESHRE Congress, we continue to share more information about OXO-001 at the most relevant congresses worldwide. In this case, […]
OXOLIFE IS PRESENT IN THE 4YFN – MWC
Today, Oxolife founders Agnès Arbat and Ignasi Canals are in the international event 4YFN – 4 Years from Now, hold in Barcelona. We are one of the startups in the BStartup’s stand from Banco Sabadell program. Oxolife keeps gaining recognition in an innovative and entrepreneurial atmosphere! Delighted to be there! #growwithus
OXOLIFE has two accepted communications in the ESHRE Annual Meeting
The European Society of Human Reproduction and Embryology (ESHRE) has accepted our second communication for its presentation during the ESHRE 37th Annual Meeting, virtually hold by the end of June. This communication is titled “OXO-001 increases embryo adhesion through a direct effect on endometrial cells” and contains information about OXO-001 in vitro studies. #growwithus
Oxolife has been recognized as an innovative SME
The Ministry of Science and Innovation has awarded us the seal of small and medium-sized innovative company. From now on, you can see this badge on our website www.oxolife.com, we are delighted to have received this recognition. #growwithus
The phase II clinical trial protocol and documents have been submitted!
Today we have a BIG new! We want to announce that the protocol and documents for the phase II clinical trial of OXO-001 have already been submitted to the three corresponding Regulatory Agencies and Ethics Committees. We have achieved a very important milestone, but mainly, we are closer to the start of OXOART 2, the […]